vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Compass Diversified Holdings (CODI). Click either name above to swap in a different company.
Compass Diversified Holdings is the larger business by last-quarter revenue ($468.6M vs $247.1M, roughly 1.9× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -16.8%, a 27.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -5.1%). Compass Diversified Holdings produced more free cash flow last quarter ($36.9M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 6.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Compass Diversified Holdings is a publicly traded holding firm that acquires and operates a diverse portfolio of middle-market businesses across sectors including consumer goods, industrial manufacturing, outdoor recreation, and food & beverage. It partners with portfolio company leadership teams to drive long-term operational growth and value creation, primarily serving North American markets.
ANIP vs CODI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $468.6M |
| Net Profit | $27.5M | $-78.8M |
| Gross Margin | — | 43.1% |
| Operating Margin | 14.1% | 9.8% |
| Net Margin | 11.1% | -16.8% |
| Revenue YoY | 29.6% | -5.1% |
| Net Profit YoY | 367.5% | -14.4% |
| EPS (diluted) | $1.14 | $-0.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $468.6M | ||
| Q3 25 | $227.8M | $472.6M | ||
| Q2 25 | $211.4M | $478.7M | ||
| Q1 25 | $197.1M | $453.8M | ||
| Q4 24 | $190.6M | $493.9M | ||
| Q3 24 | $148.3M | $456.6M | ||
| Q2 24 | $138.0M | $426.7M | ||
| Q1 24 | $137.4M | $410.8M |
| Q4 25 | $27.5M | $-78.8M | ||
| Q3 25 | $26.6M | $-74.0M | ||
| Q2 25 | $8.5M | $-51.2M | ||
| Q1 25 | $15.7M | $-30.0M | ||
| Q4 24 | $-10.3M | $-68.9M | ||
| Q3 24 | $-24.2M | $-36.0M | ||
| Q2 24 | $-2.3M | $-73.1M | ||
| Q1 24 | $18.2M | $-56.2M |
| Q4 25 | — | 43.1% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.1% | ||
| Q2 24 | — | 44.1% | ||
| Q1 24 | — | 42.6% |
| Q4 25 | 14.1% | 9.8% | ||
| Q3 25 | 15.9% | -2.3% | ||
| Q2 25 | 6.6% | -5.7% | ||
| Q1 25 | 13.3% | 0.8% | ||
| Q4 24 | -2.3% | -3.8% | ||
| Q3 24 | -13.8% | 1.8% | ||
| Q2 24 | 3.7% | 1.8% | ||
| Q1 24 | 14.8% | -2.9% |
| Q4 25 | 11.1% | -16.8% | ||
| Q3 25 | 11.7% | -15.7% | ||
| Q2 25 | 4.0% | -10.7% | ||
| Q1 25 | 8.0% | -6.6% | ||
| Q4 24 | -5.4% | -13.9% | ||
| Q3 24 | -16.3% | -7.9% | ||
| Q2 24 | -1.7% | -17.1% | ||
| Q1 24 | 13.2% | -13.7% |
| Q4 25 | $1.14 | $-0.91 | ||
| Q3 25 | $1.13 | $-1.21 | ||
| Q2 25 | $0.36 | $-0.88 | ||
| Q1 25 | $0.69 | $-0.59 | ||
| Q4 24 | $-0.45 | $-0.57 | ||
| Q3 24 | $-1.27 | $-0.62 | ||
| Q2 24 | $-0.14 | $-1.12 | ||
| Q1 24 | $0.82 | $-1.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $68.0M |
| Total DebtLower is stronger | — | $1.9B |
| Stockholders' EquityBook value | $540.7M | $442.0M |
| Total Assets | $1.4B | $3.0B |
| Debt / EquityLower = less leverage | — | 4.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $68.0M | ||
| Q3 25 | $262.6M | $61.1M | ||
| Q2 25 | $217.8M | $73.8M | ||
| Q1 25 | $149.8M | $146.2M | ||
| Q4 24 | $144.9M | $59.7M | ||
| Q3 24 | $145.0M | $64.9M | ||
| Q2 24 | $240.1M | $61.5M | ||
| Q1 24 | $228.6M | $59.5M |
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.7B |
| Q4 25 | $540.7M | $442.0M | ||
| Q3 25 | $505.8M | $519.2M | ||
| Q2 25 | $436.8M | $601.9M | ||
| Q1 25 | $418.6M | $680.7M | ||
| Q4 24 | $403.7M | $678.6M | ||
| Q3 24 | $405.9M | $672.2M | ||
| Q2 24 | $455.8M | $711.3M | ||
| Q1 24 | $452.0M | $799.7M |
| Q4 25 | $1.4B | $3.0B | ||
| Q3 25 | $1.4B | $3.2B | ||
| Q2 25 | $1.3B | $3.3B | ||
| Q1 25 | $1.3B | $3.4B | ||
| Q4 24 | $1.3B | $3.3B | ||
| Q3 24 | $1.3B | $3.3B | ||
| Q2 24 | $920.8M | $3.2B | ||
| Q1 24 | $914.5M | $3.3B |
| Q4 25 | — | 4.25× | ||
| Q3 25 | — | 3.62× | ||
| Q2 25 | — | 3.09× | ||
| Q1 25 | — | 2.73× | ||
| Q4 24 | — | 2.61× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | 2.42× | ||
| Q1 24 | — | 2.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $47.0M |
| Free Cash FlowOCF − Capex | $29.1M | $36.9M |
| FCF MarginFCF / Revenue | 11.8% | 7.9% |
| Capex IntensityCapex / Revenue | 0.5% | 2.2% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-51.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $47.0M | ||
| Q3 25 | $44.1M | $10.7M | ||
| Q2 25 | $75.8M | $-35.2M | ||
| Q1 25 | $35.0M | $-29.3M | ||
| Q4 24 | $15.9M | $-16.1M | ||
| Q3 24 | $12.5M | $-48.4M | ||
| Q2 24 | $17.4M | $-61.3M | ||
| Q1 24 | $18.3M | $-25.4M |
| Q4 25 | $29.1M | $36.9M | ||
| Q3 25 | $38.0M | $481.0K | ||
| Q2 25 | $71.8M | $-46.0M | ||
| Q1 25 | $32.5M | $-42.4M | ||
| Q4 24 | $13.5M | $-39.0M | ||
| Q3 24 | $7.7M | $-63.5M | ||
| Q2 24 | $13.0M | $-72.2M | ||
| Q1 24 | $13.7M | $-33.1M |
| Q4 25 | 11.8% | 7.9% | ||
| Q3 25 | 16.7% | 0.1% | ||
| Q2 25 | 34.0% | -9.6% | ||
| Q1 25 | 16.5% | -9.4% | ||
| Q4 24 | 7.1% | -7.9% | ||
| Q3 24 | 5.2% | -13.9% | ||
| Q2 24 | 9.4% | -16.9% | ||
| Q1 24 | 10.0% | -8.1% |
| Q4 25 | 0.5% | 2.2% | ||
| Q3 25 | 2.7% | 2.2% | ||
| Q2 25 | 1.9% | 2.3% | ||
| Q1 25 | 1.3% | 2.9% | ||
| Q4 24 | 1.3% | 4.6% | ||
| Q3 24 | 3.2% | 3.3% | ||
| Q2 24 | 3.2% | 2.6% | ||
| Q1 24 | 3.3% | 1.9% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CODI
| Other | $119.5M | 26% |
| A5.11Tactical | $113.9M | 24% |
| Sterno Products | $85.9M | 18% |
| Altor | $60.8M | 13% |
| The Honey Pot | $36.0M | 8% |
| Arnold | $25.4M | 5% |
| Velocity Outdoor | $18.7M | 4% |
| Lugano | $8.3M | 2% |
